Sec Form 4 Filing - SHEMA SUZANNE M @ ONYX PHARMACEUTICALS INC - 2013-04-08

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
SHEMA SUZANNE M
2. Issuer Name and Ticker or Trading Symbol
ONYX PHARMACEUTICALS INC [ ONXX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP, GC and Corp. Secretary
(Last) (First) (Middle)
C/O ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE.
3. Date of Earliest Transaction (MM/DD/YY)
04/08/2013
(Street)
SOUTH SAN FRANCISCO, CA94080
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/08/2013 M 656 A $ 30.28 35,274 D
Common Stock 04/08/2013 M 1,214 A $ 32.07 36,488 D
Common Stock 04/08/2013 S 1,870 ( 1 ) ( 2 ) D $ 89.1927 34,618 D
Common Stock 04/08/2013 M 583 A $ 37.68 35,201 D
Common Stock 04/08/2013 M 796 A $ 37.68 35,997 D
Common Stock 04/08/2013 S 1,379 ( 1 ) ( 2 ) D $ 89.1605 34,618 D
Common Stock 04/08/2013 M 803 A $ 35.18 35,421 D
Common Stock 04/08/2013 S 803 ( 1 ) ( 2 ) D $ 89.1603 34,618 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 30.28 04/08/2013 M 656 ( 3 ) 03/31/2020 Common Stock 656 $ 0 7,875 D
Stock Option (Right to Buy) $ 32.07 04/08/2013 M 1,214 ( 4 ) 08/31/2019 Common Stock 1,214 $ 0 18,544 D
Stock Option (Right to Buy) $ 37.68 04/08/2013 M 583 ( 5 ) 03/29/2022 Common Stock 583 $ 0 21,000 D
Stock Option (Right to Buy) $ 37.68 04/08/2013 M 796 ( 6 ) 03/29/2022 Common Stock 796 $ 0 28,649 D
Stock Option (Right to Buy) $ 35.18 04/08/2013 M 803 ( 7 ) 03/31/2021 Common Stock 803 $ 0 19,250 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SHEMA SUZANNE M
C/O ONYX PHARMACEUTICALS, INC.
249 E. GRAND AVE.
SOUTH SAN FRANCISCO, CA94080
EVP, GC and Corp. Secretary
Signatures
/s/ Matthew Fust, Attorney-in-fact 04/10/2013
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Shares sold pursuant to a 10b5-1 plan.
( 2 )The shares were sold at prices ranging from $89.0101 to $89.5601. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
( 3 )12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
( 4 )Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and beceome exercisable at a rate of 1/48th per month thereafter.
( 5 )The shares vest monthly from the date of grant at a rate of 1/48th per month over a period of 48 months.
( 6 )12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
( 7 )12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.